<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FLURBIPROFEN - flurbiprofen tablet, film coated </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_db87b37e-c8d5-4967-a523-280b287c133a"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Cardiovascular Risk</span></p>
<ul>
<li>NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see <a href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0">WARNINGS</a>).</li>
<li>Flurbiprofen is contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery (see <a href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0">WARNINGS</a>).</li>
</ul>
<p><span class="Bold">Gastrointestinal Risk</span></p>
<ul><li>NSAIDs cause an increased risk of serious gastrointestinal adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see <a href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0">WARNINGS</a>).</li></ul>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_72e19b7b-cec6-4202-86fe-976c23c88981"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Flurbiprofen is a member of the phenylalkanoic acid derivative group of non-steroidal anti-inflammatory drugs. Flurbiprofen tablets are beige, round, film-coated tablets for oral administration. Flurbiprofen is a racemic mixture of (+)S- and (-)R-enantiomers. Flurbiprofen, USP is a white or slightly yellow crystalline powder. It is slightly soluble in water at pH 7.0 and readily soluble in most polar solvents. The chemical name is [1,1’-biphenyl]-4-acetic acid, 2-fluoro-alpha-methyl-, (±)-. The molecular weight is 244.26. Its molecular formula is C<span class="Sub">15</span>H<span class="Sub">13</span>FO<span class="Sub">2</span> and it has the following structural formula:</p>
<div class="Figure">
<img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c9449292-e81e-486a-84e1-bb9dd0f612c5&amp;name=0c5d2049-9a48-4721-a893-7ea7e2612e2d-01.jpg"><p class="MultiMediaCaption"></p>
</div>
<p>Each tablet, for oral administration, contains 50 mg or 100 mg flurbiprofen, USP. Inactive ingredients are colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose (anhydrous), magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium lauryl sulfate, titanium dioxide, triacetin, yellow iron oxide and black iron oxide.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_40a22834-dae2-460d-a541-9c2fd4a96674"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_d5b28a03-28f9-44d8-bfd2-edc22f35d6d7"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">Flurbiprofen is a non-steroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of flurbiprofen, like that of other non-steroidal anti-inflammatory drugs, is not completely understood but may be related to prostaglandin synthetase inhibition.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_f1d9c3f6-e3b9-42ac-97df-3750a58c2aa7"></a><a name="section-2.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ade332f-e94b-40aa-b584-2caa1a15b032"></a><a name="section-2.2.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">The mean oral bioavailability of flurbiprofen 100 mg tablets is 96% relative to an oral solution. Flurbiprofen is rapidly and non-stereoselectively absorbed with peak plasma concentrations occurring at about 2 hours (see <a href="#id_dba33001-303b-4091-84a5-9dfedc373c75">Table 1</a>). Administration of flurbiprofen with either food or antacids may alter the rate but not the extent of flurbiprofen absorption. Ranitidine has been shown to have no effect on either the rate or extent of flurbiprofen absorption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f1bcde67-e024-4f0d-b4d3-b40a1e778dc4"></a><a name="section-2.2.2"></a><p></p>
<h3>Distribution</h3>
<p class="First">The apparent volume of distribution (Vz/F) of both R- and S-flurbiprofen is approximately 0.12 L/Kg. Both flurbiprofen enantiomers are more than 99% bound to plasma proteins, primarily albumin. Plasma protein binding is relatively constant for the typical average steady-state concentrations (≤ 10 mcg/mL) achieved with recommended doses. Flurbiprofen is poorly excreted into human milk. The nursing infant dose is predicted to be approximately 0.1 mg/day in the established milk of a woman taking flurbiprofen 200 mg/day (see <a href="#i4i_nursing_mothers_id_d25e34ea-0ec7-49b8-b901-14b5904e634e">PRECAUTIONS: Nursing Mothers</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab6a50f5-b244-4b91-adce-a8b995c1230d"></a><a name="section-2.2.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Several flurbiprofen metabolites have been identified in human plasma and urine. These metabolites include 4'-hydroxy-flurbiprofen, 3', 4'-dihydroxy-flurbiprofen, 3'-hydroxy-4'-methoxy-flurbiprofen, their conjugates, and conjugated flurbiprofen. Unlike other arylpropionic acid derivatives (e.g., ibuprofen), metabolism of R-flurbiprofen to S-flurbiprofen is minimal. <span class="Italics">In vitro</span> studies have demonstrated that cytochrome P450 2C9 plays an important role in the metabolism of flurbiprofen to its major metabolite, 4'-hydroxy-flurbiprofen. The 4'-hydroxy-flurbiprofen metabolite showed little anti-inflammatory activity in animal models of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. Flurbiprofen does not induce enzymes that alter its metabolism.</p>
<p>The total plasma clearance of unbound flurbiprofen is not stereoselective, and clearance of flurbiprofen is independent of dose when used within the therapeutic range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_375c8858-90ca-4ce6-b0f9-2a3690427c46"></a><a name="section-2.2.4"></a><p></p>
<h3>Excretion</h3>
<p class="First">Following dosing with flurbiprofen, less than 3% of flurbiprofen is excreted unchanged in the urine, with about 70% of the dose eliminated in the urine as parent drug and metabolites. Because renal elimination is a significant pathway of elimination of flurbiprofen metabolites, dosing adjustment in patients with moderate or severe renal dysfunction may be necessary to avoid accumulation of flurbiprofen metabolites. The mean terminal disposition half-lives (t<span class="Sub">1/2</span>) of R- and S-flurbiprofen are similar, about 4.7 and 5.7 hours, respectively. There is little accumulation of flurbiprofen following multiple doses of flurbiprofen.</p>
<a name="id_dba33001-303b-4091-84a5-9dfedc373c75"></a><table width="0.000">
<caption><span>Table 1. Mean (SD) R, S-Flurbiprofen Pharmacokinetic Parameters Normalized to a 100 mg Dose of Flurbiprofen</span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First">Pharmacokinetic</p>Parameter</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Normal Healthy</p>
<p>Adults
                                          </p>
<p>(18 to 40 years)</p>N = 15</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Geriatric</p>
<p><span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">Arthritis</span> Patients
                                          </p>
<p>(65 to 83 years)</p>N = 13</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">End Stage Renal</p>
<p>Disease Patients<span class="Sup">*</span></p>
<p>(23 to 42 years)</p>N = 8</td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Alcoholic</p>
<p>Cirrhosis Patients
                                          </p>
<p>(31 to 61 years)</p>N = 8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Peak</p>
<p>Concentration</p>(Tg/mL)</td>
<td class="Botrule Rrule" align="center" valign="top">14 (4)</td>
<td class="Botrule Rrule" align="center" valign="top">16 (5)</td>
<td class="Botrule Rrule" align="center" valign="top">9
                                       </td>
<td class="Botrule Rrule" align="center" valign="top">9<span class="Sup">§</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Time of Peak</p>
<p>Concentration</p>(h)</td>
<td class="Botrule Rrule" align="center" valign="top">1.9 (1.5)</td>
<td class="Botrule Rrule" align="center" valign="top">2.2 (3)</td>
<td class="Botrule Rrule" align="center" valign="top">2.3<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">1.2<span class="Sup">§</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Urinary Recovery</p>
<p>of Unchanged</p>
<p>Flurbiprofen</p>(% of Dose)</td>
<td class="Botrule Rrule" align="center" valign="top">2.9 (1.3)</td>
<td class="Botrule Rrule" align="center" valign="top">0.6 (0.6)</td>
<td class="Botrule Rrule" align="center" valign="top">0.02 (0.02)</td>
<td class="Botrule Rrule" align="center" valign="top">NA
                                       </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Area Under the</p>
<p>Curve (AUC)
                                          </p>(Tg h/mL)</td>
<td class="Botrule Rrule" align="center" valign="top">83 (20)</td>
<td class="Botrule Rrule" align="center" valign="top">77 (24)</td>
<td class="Botrule Rrule" align="center" valign="top">44<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">50<span class="Sup">§</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Apparent Volume</p>
<p>of Distribution</p>(Vz/F, L)</td>
<td class="Botrule Rrule" align="center" valign="top">14 (3)</td>
<td class="Botrule Rrule" align="center" valign="top">12 (5)</td>
<td class="Botrule Rrule" align="center" valign="top">10<span class="Sup">§</span>
</td>
<td class="Botrule Rrule" align="center" valign="top">14<span class="Sup">§</span>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">
<p class="First">Terminal</p>
<p>Disposition</p>Half-life (t<span class="Sub">1/2</span>, h)</td>
<td class="Rrule" align="center" valign="top">7.5 (0.8)</td>
<td class="Rrule" align="center" valign="top">5.8 (1.9)</td>
<td class="Rrule" align="center" valign="top">3.3
                                       </td>
<td class="Botrule Rrule" align="center" valign="top">5.4<span class="Sup">Þ</span>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b7c7a8e-d7c0-4da1-b4db-d94df5f70c90"></a><a name="section-2.3"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e272c3b0-9fd9-476d-afc1-8d00dc92a28b"></a><a name="section-2.3.1"></a><p></p>
<h3>Pediatric</h3>
<p class="First">The pharmacokinetics of flurbiprofen have not been investigated in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_df832be4-1727-4a63-b1ef-dc2e9ebef21e"></a><a name="section-2.3.2"></a><p></p>
<h3>Race</h3>
<p class="First">No pharmacokinetic differences due to race have been identified.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2c1e2d4b-a917-40fb-9077-520db6390039"></a><a name="section-2.3.3"></a><p></p>
<h3>Geriatric</h3>
<p class="First">Flurbiprofen pharmacokinetics were similar in geriatric <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> patients, younger <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> patients, and young healthy volunteers receiving flurbiprofen tablets 100 mg as either single or multiple doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a9f515fc-00a2-44fe-bcfc-8022691e9e15"></a><a name="section-2.3.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></h3>
<p class="First">Hepatic metabolism may account for &gt; 90% of flurbiprofen elimination, so patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> may require reduced doses of flurbiprofen tablets compared to patients with normal hepatic function. The pharmacokinetics of R- and S-flurbiprofen were similar, however, in <span class="product-label-link" type="condition" conceptid="196463" conceptname="Alcoholic cirrhosis">alcoholic cirrhosis</span> patients (N = 8) and young healthy volunteers (N = 8) following administration of a single 200 mg dose of flurbiprofen tablets. </p>
<p>Flurbiprofen plasma protein binding may be decreased in patients with liver disease and serum albumin concentrations below 3.1 g/dL (see <span class="Italics"><a href="#i4i_section_id_a662a4fa-cf6e-46d6-aeda-8d1f5ce60673">PRECAUTIONS: General: Hepatic Effects</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6b08cd5a-0d9e-4bb6-a0b8-20807d7dea67"></a><a name="section-2.3.5"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></h3>
<p class="First">Renal clearance is an important route of elimination for flurbiprofen metabolites, but a minor route of elimination for unchanged flurbiprofen (≤ 3% of total clearance). The unbound clearances of R- and S-flurbiprofen did not differ significantly between normal healthy volunteers (N = 6, 50 mg single dose) and patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (N = 8, inulin clearances ranging from 11 to 43 mL/min, 50 mg multiple doses). Flurbiprofen plasma protein binding may be decreased in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and serum albumin concentrations below 3.9 g/dL. Elimination of flurbiprofen metabolites may be reduced in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (see <span class="Italics"><a href="#i4i_precautions_general_id_562c82d9-349b-433a-b09a-c166605fd305">PRECAUTIONS: General: Renal Effects</a></span>).</p>
<p>Flurbiprofen is not significantly removed from the blood into dialysate in patients undergoing continuous ambulatory peritoneal dialysis.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9f205ed-34bd-457b-a579-b97a67cf1c71"></a><a name="section-2.4"></a><p></p>
<h2>Drug-Drug Interactions</h2>
<p class="First"><span class="Bold">(see also <span class="Bold"><a href="#i4i_interactions_id_73bf8e01-6038-4f66-a8d1-8f9ec0c57815">PRECAUTIONS: Drug Interactions</a></span>)</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cc58c2a3-722e-443b-8a87-753dacae5101"></a><a name="section-2.4.1"></a><p></p>
<h3>Antacids</h3>
<p class="First">Administration of flurbiprofen to volunteers under fasting conditions or with antacid suspension yielded similar serum flurbiprofen-time profiles in young adult subjects (n = 12). In geriatric subjects (n = 7), there was a reduction in the rate but not the extent of flurbiprofen absorption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6f23b519-0936-4a96-968c-082f44e3b600"></a><a name="section-2.4.2"></a><p></p>
<h3>Aspirin</h3>
<p class="First">Concurrent administration of flurbiprofen and aspirin resulted in 50% lower serum flurbiprofen concentrations. This effect of aspirin (which is also seen with other non-steroidal anti-inflammatory drugs) has been demonstrated in patients with <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> (n = 15) and in healthy volunteers (n = 16) (see <a href="#i4i_interactions_id_73bf8e01-6038-4f66-a8d1-8f9ec0c57815">PRECAUTIONS: Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cabd5909-b700-4b79-b1bf-8f37d6636e99"></a><a name="section-2.4.3"></a><p></p>
<h3>Beta-Adrenergic Blocking Agents</h3>
<p class="First">The effect of flurbiprofen on blood pressure response to propranolol and atenolol was evaluated in men with mild <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncomplicated hypertension</span> (n = 10). Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of propranolol but not atenolol. Flurbiprofen did not appear to affect the beta-blocker-mediated reduction in heart rate. Flurbiprofen did not affect the pharmacokinetic profile of either drug (see <a href="#i4i_interactions_id_73bf8e01-6038-4f66-a8d1-8f9ec0c57815">PRECAUTIONS: Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_03db3f5f-61eb-4d6c-8a8d-2f5bca464b00"></a><a name="section-2.4.4"></a><p></p>
<h3>Cimetidine, Ranitidine</h3>
<p class="First">In normal volunteers (n = 9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics, except for a small (13%) but statistically significant increase in the area under the serum concentration curve of flurbiprofen in subjects who received cimetidine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_83381a6b-b711-49b2-990b-b4f0ff17251e"></a><a name="section-2.4.5"></a><p></p>
<h3>Digoxin</h3>
<p class="First">In studies of healthy males (n = 14), concomitant administration of flurbiprofen and digoxin did not change the steady-state serum levels of either drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d1018c9c-adc1-49a7-94eb-212a6e0e86e7"></a><a name="section-2.4.6"></a><p></p>
<h3>Diuretics</h3>
<p class="First">Studies in healthy volunteers have shown that, like other non-steroidal anti-inflammatory drugs, flurbiprofen can interfere with the effects of furosemide. Although results have varied from study to study, effects have been shown on furosemide-stimulated <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, natriuresis, and kaliuresis. Other non-steroidal anti-inflammatory drugs that inhibit prostaglandin synthesis have been shown to interfere with thiazide and potassium-sparing diuretics (see <a href="#i4i_interactions_id_73bf8e01-6038-4f66-a8d1-8f9ec0c57815">PRECAUTIONS: Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ddefbb6-bad0-4216-8c80-414f6f20fce4"></a><a name="section-2.4.7"></a><p></p>
<h3>Lithium</h3>
<p class="First">In a study of 11 women with bipolar disorder receiving lithium carbonate at a dosage of 600 mg to 1200 mg/day, administration of 100 mg flurbiprofen every 12 hours increased plasma lithium concentrations by 19%. Four of 11 patients experienced a clinically important increase (&gt; 25% or &gt; 0.2 mmol/L). Non-steroidal anti-inflammatory drugs have also been reported to decrease the renal clearance of lithium by about 20% (see <a href="#i4i_interactions_id_73bf8e01-6038-4f66-a8d1-8f9ec0c57815">PRECAUTIONS: Drug Interactions</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bead1324-11d7-4d35-bd0d-650b6b1d6b8c"></a><a name="section-2.4.8"></a><p></p>
<h3>Methotrexate</h3>
<p class="First">In a study of six adult <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> patients, coadministration of methotrexate (10 to 25 mg/dose) and flurbiprofen (300 mg/day) resulted in no observable interaction between these two drugs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_65b03665-35f4-4558-a54b-86726b91fa2d"></a><a name="section-2.4.9"></a><p></p>
<h3>Oral Hypoglycemic Agents</h3>
<p class="First">In a clinical study, flurbiprofen was administered to adult diabetics who were already receiving glyburide (n = 4), metformin (n = 2), chlorpropamide with phenformin (n = 3), or glyburide with phenformin (n = 6). Although there was a slight reduction in blood sugar concentrations during concomitant administration of flurbiprofen and hypoglycemic agents, there were no signs or symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_c8adda3d-3c3a-4807-bf45-fc5fe766dae4"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Carefully consider the potential benefits and risks of flurbiprofen tablets and other treatment options before deciding to use flurbiprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <a href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0">WARNINGS</a>).</p>
<p>Flurbiprofen tablets are indicated:</p>
<ul>
<li>For relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>.</li>
<li>For relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_e118260c-6d3a-403f-9e90-11277c717f2a"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Flurbiprofen tablets are contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to flurbiprofen tablets or the excipients (see <a href="#i4i_description_id_72e19b7b-cec6-4202-86fe-976c23c88981">DESCRIPTION</a>).</p>
<p> Flurbiprofen should not be given to patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs. Severe, rarely fatal, anaphylactic-like reactions to non-steroidal anti-inflammatory drugs have been reported in such patients (see <a href="#i4i_section_id_6d9e24e5-eeb5-46fb-b5e5-020f2889a65f">WARNINGS: <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a> and <span class="Italics"><a href="#i4i_section_id_6828baed-f416-4913-8a3d-0ae8f70881b3">PRECAUTIONS: General: Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></span>). </p>
<p> Flurbiprofen is contraindicated for the treatment of perioperative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery (see <a href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_14d2419f-441b-4445-9319-6af08c4535f2"></a><a name="section-5.1"></a><p></p>
<h2>Cardiovascular Effects</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d53f9a44-40b1-458d-804f-ef3d55100296"></a><a name="section-5.1.1"></a><p></p>
<h3>Cardiovascular Thrombotic Events</h3>
<p class="First">Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, the lowest effective dose should be used for the shortest duration possible. Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Patients should be informed about the signs and/or symptoms of serious CV events and the steps to take if they occur.</p>
<p> There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID does increase the risk of serious GI events (see <a href="#i4i_section_id_710dcb11-5e4f-4514-a453-c1d2b17d9b46">WARNINGS: Gastrointestinal Effects</a>).</p>
<p> Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10 to 14 days following CABG surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (see <a href="#i4i_contraindications_id_e118260c-6d3a-403f-9e90-11277c717f2a">CONTRAINDICATIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80fee509-268b-4b94-9fd1-152c56cf643f"></a><a name="section-5.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h3>
<p class="First">NSAIDs, including flurbiprofen, can lead to onset of new <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or worsening of preexisting <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. NSAIDs, including flurbiprofen, should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Blood pressure (BP) should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_200fb1d7-cda4-4bf5-a54d-0ed88712547d"></a><a name="section-5.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients taking NSAIDs. Flurbiprofen should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_710dcb11-5e4f-4514-a453-c1d2b17d9b46"></a><a name="section-5.2"></a><p></p>
<h2>Gastrointestinal Effects</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_890d0f40-1001-4b17-ac47-978eb3264f23"></a><a name="section-5.2.1"></a><p></p>
<h3>Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</h3>
<p class="First">NSAIDs, including flurbiprofen, can cause serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients, who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3 to 6 months, and in about 2% to 4% of patients treated for one year. These trends continue with longer duration of use, increasing the likelihood of developing a serious GI event at some time during the course of therapy. However, even short-term therapy is not without risk.</p>
<p> NSAIDs should be prescribed with extreme caution in those with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>. Patients with a <span class="Italics">prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span> </span>who use NSAIDs have a greater than 10-fold increased risk for developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> compared to patients treated with neither of these risk factors. Other factors that increase the risk of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. Most spontaneous reports of fatal GI events are in elderly or debilitated patients and therefore, special care should be taken in treating this population. </p>
<p> To minimize the potential risk for an adverse GI event in patients treated with an NSAID, the lowest effective dose should be used for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during NSAID therapy and promptly initiate additional evaluation and treatment if a serious GI event is suspected. This should include discontinuation of the NSAID until a serious GI adverse event is ruled out. For high risk patients, alternate therapies that do not involve NSAIDs should be considered. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_50d6c226-dbeb-4ca6-aa4e-27ee7c5cbe6c"></a><a name="section-5.3"></a><p></p>
<h2>Renal Effects</h2>
<p class="First">Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of a non-steroidal anti-inflammatory drug may cause a dose dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_52cc338d-9c6f-4ec9-a8fa-9289a09440b7"></a><a name="section-5.3.1"></a><p></p>
<h3>Advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span></h3>
<p class="First">In clinical studies, the elimination half-life of flurbiprofen was unchanged in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Flurbiprofen metabolites are eliminated primarily by the kidneys. Elimination of 4'-hydroxy-flurbiprofen was reduced in patients with moderate to severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Therefore, treatment with flurbiprofen is not recommended in these patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. If flurbiprofen therapy must be initiated, close monitoring of the patients renal function is advisable (see <a href="#i4i_clinical_pharmacology_id_40a22834-dae2-460d-a541-9c2fd4a96674">CLINICAL PHARMACOLOGY</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d9e24e5-eeb5-46fb-b5e5-020f2889a65f"></a><a name="section-5.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">As with other NSAIDs, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in patients without known prior exposure to flurbiprofen. Flurbiprofen should not be given to patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs (see <a href="#i4i_contraindications_id_e118260c-6d3a-403f-9e90-11277c717f2a">CONTRAINDICATIONS</a> and <span class="Italics"><a href="#i4i_section_id_6828baed-f416-4913-8a3d-0ae8f70881b3">PRECAUTIONS: General: Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></span>). Emergency help should be sought in cases where an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c3b0a24-f38a-4bba-8b7b-a19d8f3ece14"></a><a name="section-5.5"></a><p></p>
<h2>Pregnancy</h2>
<p class="First">In late pregnancy, as with other NSAIDs, flurbiprofen should be avoided because it may cause premature closure of the ductus arteriosus.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_03effa84-5701-4d42-8589-68e2cb55a195"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_562c82d9-349b-433a-b09a-c166605fd305"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Flurbiprofen cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids.</p>
<p> The pharmacological activity of flurbiprofen in reducing <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a662a4fa-cf6e-46d6-aeda-8d1f5ce60673"></a><a name="section-6.1.1"></a><p></p>
<h3>Hepatic Effects</h3>
<p class="First">Borderline elevations of one or more liver tests may occur in up to 15% of patients taking non-steroidal anti-inflammatory drugs, including flurbiprofen. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevations of ALT or AST (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials with non-steroidal anti-inflammatory drugs. In addition, rare cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, some of them with fatal outcomes have been reported.</p>
<p> A patient with symptoms and/or signs suggesting liver dysfunction, or with abnormal liver test values, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with flurbiprofen. If clinical signs and symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.), flurbiprofen should be discontinued. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_234c0ec3-dffe-4d5c-927b-d36d90234bd8"></a><a name="section-6.1.2"></a><p></p>
<h3>Hematological Effects</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> is sometimes seen in patients receiving non-steroidal anti-inflammatory drugs, including flurbiprofen. This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, GI blood loss, or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with non-steroidal anti-inflammatory drugs, including flurbiprofen, should have their hemoglobin or hematocrit checked periodically even if they do not exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.</p>
<p> Non-steroidal anti-inflammatory drugs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Flurbiprofen does not generally affect platelet counts, <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT), or partial thromboplastin time (PTT). Patients receiving flurbiprofen who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants, should be carefully monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6828baed-f416-4913-8a3d-0ae8f70881b3"></a><a name="section-6.1.3"></a><p></p>
<h3>Preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h3>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> which can be fatal. Since cross-reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other non-steroidal anti-inflammatory drugs has been reported in such aspirin-sensitive patients, flurbiprofen should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2893f495-fa42-47c2-ac01-fb5a7c853a9e"></a><a name="section-6.1.4"></a><p></p>
<h3>Vision Changes</h3>
<p class="First">Blurred and/or diminished vision has been reported with the use of flurbiprofen and other non-steroidal anti-inflammatory drugs. Patients experiencing eye complaints should have ophthalmologic examinations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_485e5d57-b265-43cf-aa88-bf508407a6f2"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be informed of the following information before initiating therapy with an NSAID and periodically during the course of ongoing therapy. Patients should also be encouraged to read the NSAID Medication Guide that accompanies each prescription dispensed.</p>
<ul>
<li>Flurbiprofen, like other NSAIDs, may cause CV side effects, such as MI or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious CV events can occur without warning symptoms, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up (see <a href="#i4i_section_id_14d2419f-441b-4445-9319-6af08c4535f2">WARNINGS: Cardiovascular Effects</a>).</li>
<li>Flurbiprofen, like other NSAIDs, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and, rarely, serious GI side effects, such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and should ask for medical advice when observing any indicative sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Patients should be apprised of the importance of this follow-up (see <span class="Italics"><a href="#i4i_section_id_890d0f40-1001-4b17-ac47-978eb3264f23">WARNINGS: Gastrointestinal Effects: Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation</a></span>).</li>
<li>Flurbiprofen, like other NSAIDs, can cause serious skin side effects such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, SJS, and TEN, which may result in hospitalizations and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, patients should be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and should ask for medical advice when observing any indicative signs or symptoms. Patients should be advised to stop the drug immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and contact their physicians as soon as possible. </li>
<li>Patients should promptly report signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> to their physicians.</li>
<li>Patients should be informed of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> and “flu-like? symptoms). If these occur, patients should be instructed to stop therapy and seek immediate medical therapy.</li>
<li>Patients should be informed of the signs of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (e.g. <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). If these occur, patients should be instructed to seek immediate emergency help (see <a href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0">WARNINGS</a>).</li>
<li>In late pregnancy, as with other NSAIDs, flurbiprofen should be avoided because it may cause premature closure of the ductus arteriosus.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_0aaf18b5-6ae7-4c5c-b9db-86dc6f67ff1b"></a><a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Because serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients on long-term treatment with non-steroidal anti-inflammatory drugs should have their CBC and chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> develop, systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, etc.) or abnormal liver tests persist or worsen, flurbiprofen should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_73bf8e01-6038-4f66-a8d1-8f9ec0c57815"></a><a name="section-6.4"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_26222964-2e1a-4fb1-9cd1-7e1b7f4c04f1"></a><a name="section-6.4.1"></a><p></p>
<h3>ACE Inhibitors</h3>
<p class="First">Reports suggest that non-steroidal anti-inflammatory drugs may diminish the antihypertensive effect of ACE inhibitors. These interactions should be given consideration in patients taking non-steroidal anti-inflammatory drugs concomitantly with ACE inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f3865ba-a564-426f-874b-d6cae17b0618"></a><a name="section-6.4.2"></a><p></p>
<h3>Anticoagulants</h3>
<p class="First">The effects of warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that users of both drugs together have a risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> higher than users of either drug alone. The physician should be cautious when administering flurbiprofen to patients taking warfarin or other anticoagulants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_859ea3cd-91da-4e07-910c-4bc86fc4a396"></a><a name="section-6.4.3"></a><p></p>
<h3>Aspirin</h3>
<p class="First">Concurrent administration of aspirin lowers serum flurbiprofen concentrations (see <a href="#i4i_section_id_e9f205ed-34bd-457b-a579-b97a67cf1c71">CLINICAL PHARMACOLOGY: Drug-Drug Interactions</a>). The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of flurbiprofen and aspirin is not generally recommended because of the potential for increased adverse effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7ee6a48f-a1f2-46ca-b631-8392da035df1"></a><a name="section-6.4.4"></a><p></p>
<h3>Beta-Adrenergic Blocking Agents</h3>
<p class="First">Flurbiprofen attenuated the hypotensive effect of propranolol but not atenolol (see <a href="#i4i_section_id_e9f205ed-34bd-457b-a579-b97a67cf1c71">CLINICAL PHARMACOLOGY: Drug-Drug Interactions</a>). The mechanism underlying this interference is unknown. Patients taking both flurbiprofen and a beta-blocker should be monitored to ensure that a satisfactory hypotensive effect is achieved.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5d53c591-30c3-4a27-9162-e5b65c4cc76d"></a><a name="section-6.4.5"></a><p></p>
<h3>Diuretics</h3>
<p class="First">Clinical studies, as well as post-marketing observations, have shown that flurbiprofen can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (see <a href="#i4i_section_id_50d6c226-dbeb-4ca6-aa4e-27ee7c5cbe6c">WARNINGS: Renal Effects</a>), as well as diuretic efficacy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7c177cb-fae4-493b-b7e3-0582e4dabdf5"></a><a name="section-6.4.6"></a><p></p>
<h3>Lithium</h3>
<p class="First">NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. </p>
<p> These effects have been attributed to inhibition of renal prostaglandin synthesis by the non-steroidal anti-inflammatory drugs. Thus, when non-steroidal anti-inflammatory drugs and lithium are administered concurrently, subjects should be observed carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_80add559-71d4-48e3-b910-f507ececdc39"></a><a name="section-6.4.7"></a><p></p>
<h3>Methotrexate</h3>
<p class="First">Non-steroidal anti-inflammatory drugs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when non-steroidal anti-inflammatory drugs are administered concomitantly with methotrexate.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_97959db7-c474-4897-9d34-77b7182e07e1"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_b552ccf3-37b4-4191-a824-f0037bad8849"></a><a name="section-6.5.1"></a><p></p>
<h3>Teratogenic Effects. Pregnancy Category C</h3>
<p class="First">Reproductive studies conducted in rats and rabbits have not demonstrated evidence of developmental abnormalities. However, animal reproduction studies are not always predictive of human response. There are no adequate and well controlled studies in pregnant women. <span class="Underline">Flurbiprofen should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus</span>.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_b34580d5-3f9e-4a31-b8e1-99528b6c61f7"></a><a name="section-6.5.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Because of the known effects of non-steroidal anti-inflammatory drugs on the fetal cardiovascular system (closure of ductus arteriosus), use during late pregnancy should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_9557eaea-535e-4246-b498-cc0702d6b69f"></a><a name="section-6.6"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">In rat studies with non-steroidal anti-inflammatory drugs, as with other drugs known to inhibit prostaglandin synthesis, an increased incidence of dystocia, delayed parturition, and decreased pup survival occurred. The effects of flurbiprofen on labor and delivery in pregnant women are unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_d25e34ea-0ec7-49b8-b901-14b5904e634e"></a><a name="section-6.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Concentrations of flurbiprofen in breast milk and plasma of nursing mothers suggest that a nursing infant could receive approximately 0.10 mg flurbiprofen per day in the established milk of a woman taking flurbiprofen 200 mg/day. Because of possible adverse effects of prostaglandin-inhibiting drugs on neonates, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ffd27473-f7d2-49a3-819f-7e68f3d3a8a1"></a><a name="section-6.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_6f211012-fd93-4279-9f19-82a3a9e30708"></a><a name="section-6.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">As with any NSAID, caution should be exercised in treating the elderly (65 years and older). Clinical experience with flurbiprofen suggests that elderly patients may have a higher incidence of gastrointestinal complaints than younger patients, including ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="442597" conceptname="Swollen abdomen">bloating</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. To minimize the potential risk for gastrointestinal events, the lowest effective dose should be used for the shortest possible duration (see <a href="#i4i_section_id_710dcb11-5e4f-4514-a453-c1d2b17d9b46">WARNINGS: Gastrointestinal Effects</a>). Likewise, elderly patients are at greater risk of developing renal decompensation (see <a href="#i4i_section_id_50d6c226-dbeb-4ca6-aa4e-27ee7c5cbe6c">WARNINGS: Renal Effects</a>). </p>
<p> The pharmacokinetics of flurbiprofen do not seem to differ in elderly patients from those in younger individuals (see <a href="#i4i_section_id_6b7c7a8e-d7c0-4da1-b4db-d94df5f70c90">CLINICAL PHARMACOLOGY: Special Populations</a>). The rate of absorption of flurbiprofen was reduced in elderly patients who also received antacids, although the extent of absorption was not affected (see <a href="#i4i_section_id_e9f205ed-34bd-457b-a579-b97a67cf1c71">CLINICAL PHARMACOLOGY: Drug-Drug Interactions</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_62a168e3-f072-4819-a2a6-3b1f6bff67f9"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<a name="id_496913c3-5a71-4e15-a3e5-d99518d6f363"></a><table width="0.000">
<caption><span>TABLE 2. Reported adverse events in patients receiving flurbiprofen or other non-steroidal anti-inflammatory drugs</span></caption>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top">Reported in patients treated with flurbiprofen</td>
<td class="Botrule Rrule" align="center" rowspan="2" valign="top">
<p class="First">Reported in patients</p>
<p>treated with other</p>
<p>products but not</p>flurbiprofen</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">Incidence of 1%</p>or greater 
                           </td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Incidence &lt; 1% -</p>
<p>Causal Relationship</p>Probable
                           </td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">Incidence &lt; 1% -</p>
<p>Causal Relationship</p>Unknown <span class="Sup">†</span>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">BODY AS A WHOLE</p>     <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>anaphylactic</p>
<p>      reaction</p>
<p><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></p><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></td>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>&lt; 1%:</p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></p><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">CARDIOVASCULAR</p> SYSTEM</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>congestive heart</p>
<p>      failure</p>
<p><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></p>
<p>vascular diseases</p>vasodilation</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br><span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span></p>
<p><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span></p><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>&lt; 1%:</p>
<p><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></p>
<p><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span></p>
<p><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span></p>
<p><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span></p><span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">DIGESTIVE SYSTEM</p>
<p>    <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></p>
<p>      <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>/<span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span></p>
<p>     elevated liver enzymes</p>
<p>     <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span></p>
<p>     GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></p>     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br><span class="product-label-link" type="condition" conceptid="4318833" conceptname="Hemorrhagic diarrhea">bloody diarrhea</span></p>
<p>esophageal disease</p>
<p>gastric/<span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span></p>
<p>      disease</p>
<p><span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span></p>
<p><span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span></p>
<p>      (cholestatic and</p>
<p>      noncholestatic)</p>
<p><span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span></p>
<p><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></p><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>/<span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>appetite changes</p>
<p><span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></p>
<p>exacerbation of</p>
<p>      inflammatory</p>
<p>      bowel disease</p>
<p><span class="product-label-link" type="condition" conceptid="4103655" conceptname="Dental abscess">periodontal abscess</span></p>
<p>small intestine</p>
<p>      <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> with</p>
<p>      loss of blood and</p>      protein</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>&gt; 1%:</p>
<p><span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">GI perforation</span></p>
<p>GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span></p>
<p>      (gastric/duodenal)</p>
<p><br>&lt; 1%:</p>
<p><span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span></p>
<p><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></p>
<p><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">HEMIC AND LYMPHATIC</p>SYSTEM</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br><span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span></p>
<p>      (including</p>
<p>      <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span></p>
<p>      or <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>)</p>
<p>decrease in</p>
<p>      hemoglobin and</p>
<p>      hematocrit</p>
<p> <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>/<span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span></p>
<p><span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span></p>
<p><span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span></p>
<p>      <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leucopenia</span></p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></td>
<td class="Botrule Rrule" align="left" valign="top"><p class="First"><br><span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span></p></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>&gt; 1%:</p>
<p><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span></p>
<p>increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></p>
<p>      time</p>
<p><br>&lt; 1%:</p>
<p><span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span></p><span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">METABOLIC AND</p>
<p>NUTRITIONAL SYSTEM</p>     body weight changes</td>
<td class="Botrule Rrule" align="left" valign="top">
<br><br><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<br><br><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<br><br><p class="First">&lt; 1%:</p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">NERVOUS SYSTEM</p>
<p>     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></p>
<p>     <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> and other</p>
<p>           manifestations of</p>
<p>            central nervous</p>
<p>            system (CNS)</p>
<p>            stimulation (e.g.,</p>
<p>           <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>,</p>
<p>           increased reflexes,</p>
<p>      <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>)</p>
<p>      symptoms associated</p>
<p>            with CNS inhibition</p>
<p>           (e.g., <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>,</p>
<p>            <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>,</p>           <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>)</td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span></p>
<p>cerebrovascular</p>
<p> <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span></p>
<p><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></p><span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span></p>
<p>cerebrovascular</p>
<p>      <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span></p>
<p><span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span></p>
<p><span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span></p>
<p><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">myasthenia</span></p>
<p>subarachnoid</p>     <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>&lt; 1%:</p>
<p><span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span></p>
<p>dream abnormalities</p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span></p><span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">RESPIRATORY SYSTEM</p>      <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></p><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br><span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span> </p>
<p><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span></p>
<p><span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span></p><span class="product-label-link" type="condition" conceptid="254662" conceptname="Pulmonary infarction">pulmonary infarct</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>&lt; 1%:</p>
<p><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span></p>
<p>respiratory</p>      <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">SKIN AND APPENDAGES</p>     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span></p>
<p><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span></p>
<p>exfoliative</p>
<p>      <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span></p>
<p><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p>toxic epidermal</p>
<p>      necrolysis</p><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span></p>
<p><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span></p>
<p>herpes simplex/zoster</p>
<p><span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail disorder</span></p><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>&lt; 1%:</p>
<p><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></p>
<p>      multiforme</p>
<p>Stevens Johnson</p>      Syndrome</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">SPECIAL SENSES</p>
<p>      changes in vision</p>
<p>      <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>      <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span></p><span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>changes in taste</p>
<p><span class="product-label-link" type="condition" conceptid="378752" conceptname="Corneal opacity">corneal opacity</span></p>
<p>ear disease</p>
<p><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span></p>
<p><span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span></p>
<p><span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">retrobulbar neuritis</span></p>transient <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>&gt; 1%:</p>
<p><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
<p><br>&lt; 1%:</p>hearing impairment</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
<p class="First">UROGENITAL SYSTEM</p>
<p>     signs and symptoms</p>
<p>          suggesting urinary</p>          tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></td>
<td class="Rrule" align="left" valign="top">
<p class="First"><br><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span></p>
<p>interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span></p><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span></td>
<td class="Rrule" align="left" valign="top">
<p class="First"><br>menstrual</p>
<p>     disturbances</p>
<p>prostate disease</p>
<p>vaginal and uterine</p>
<p>      <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span></p><span class="product-label-link" type="condition" conceptid="4180978" conceptname="Vulvovaginitis">vulvovaginitis</span></td>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><br>&gt; 1%:</p>
<p>abnormal renal</p>
<p> function</p>
<p><br>&lt; 1%:</p>
<p><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span></p>
<p><span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span></p>
<p><span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span></p><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_15eef4c4-8768-490c-93ad-df4ead2332fe"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Symptoms following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdoses</span> with non-steroidal anti-inflammatory drugs are usually limited to <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, which are generally reversible with supportive care. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> can occur. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may occur, but are rare. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported with therapeutic ingestion of non-steroidal anti-inflammatory drugs, and may occur following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>Patients should be managed by symptomatic and supportive care following <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with a non-steroidal anti-inflammatory drug. There are no specific antidotes. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> and/or activated charcoal (60 g to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms, or following a large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (5 to 10 times the usual dose). Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, alkalization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_a3e21215-ba42-4114-a26a-1d4d393c38ca"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Carefully consider the potential benefits and risks of flurbiprofen and other treatment options before deciding to use flurbiprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see <a href="#i4i_warnings_id_03d32499-95c7-48cc-ab90-6ba464803ee0">WARNINGS</a>).</p>
<p> After observing the response to initial therapy with flurbiprofen, the dose and frequency should be adjusted to suit an individual patient’s needs.</p>
<p>For relief of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span> or <span class="product-label-link" type="condition" conceptid="80180" conceptname="Osteoarthritis">osteoarthritis</span>, the recommended starting dose of flurbiprofen is 200 mg to 300 mg per day, divided for administration two, three, or four times a day. The largest recommended single dose in a multiple-dose daily regimen is 100 mg.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_67d00beb-d47f-4313-becc-e503610b9947"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Flurbiprofen tablets, USP are available containing 100 mg of flurbiprofen, USP.</p>
<br><p>The 100 mg tablets are film-coated beige, round, unscored, tablets debossed with <span class="Bold">M</span> over <span class="Bold">93 </span>on one side of the tablet and blank on the other side. They are available as follows:</p>
<a name="i8c53fc03-9002-49b6-8e28-295878ffcb67"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Bottles of 20<br>
</td>
<td>NDC 54868-3362-0<br>
</td>
</tr>
<tr>
<td>Bottles of 60<br>
</td>
<td>NDC 54868-3362-1<br>
</td>
</tr>
<tr class="Last">
<td>Bottles of 100<br>
</td>
<td>NDC 54868-3362-2<br>
</td>
</tr>
</tbody></table>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p>Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.</p>
<p><span class="Bold">PHARMACIST:</span> Dispense a Medication Guide with each prescription.</p>
<p>Mylan Pharmaceuticals Inc.<br>Morgantown, WV 26505</p>
<p>REVISED JUNE 2009<br>FRB:R9mc</p>
<br><p><br></p>
<p><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, Oklahoma       74146<br></p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_e12cb92c-095e-47a5-a1b2-42109bfaf844"></a><a name="section-11"></a><p></p>
<h1>Medication Guide <br>for <br>Non-Steroidal Anti-Inflammatory Drugs <br>(NSAIDs)</h1>
<p class="First"><span class="Underline">(See the end of this Medication Guide for a list of prescription NSAID medicines.)</span></p>
<p><span class="Bold">What is the most important information I should know about medicines called Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </span></p>
<p><span class="Bold">NSAID medicines may increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span> This chance increases: </p>
<ul>
<li>with longer use of NSAID medicines </li>
<li>in people who have heart disease </li>
</ul>
<p><span class="Bold">NSAID medicines should never be used right before or after a heart surgery called a “coronary artery bypass graft (CABG).?</span></p>
<p><span class="Bold">NSAID medicines can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the stomach and intestines at any time during treatment. <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>: </span></p>
<ul>
<li>can happen without warning symptoms </li>
<li>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <dl>
<dt> </dt>
<dd>
<span class="Bold">The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with: </span><ul>
<li>taking medicines called “corticosteroids? and “anticoagulants? </li>
<li>longer use </li>
<li>smoking </li>
<li>drinking alcohol </li>
<li>older age </li>
<li>having poor health </li>
</ul>
</dd>
</dl>
</li>
</ul>
<p><span class="Bold">NSAID medicines should only be used: </span></p>
<ul>
<li>exactly as prescribed </li>
<li>at the lowest dose possible for your treatment </li>
<li>for the shortest time needed </li>
</ul>
<p><span class="Bold">What are Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </span></p>
<p>NSAID medicines are used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and heat (<span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) from medical conditions such as: </p>
<ul>
<li>different types of <span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span> </li>
<li><span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">menstrual cramps</span> and other types of short-term <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p><span class="Bold">Who should not take a Non-Steroidal Anti-Inflammatory Drug (NSAID)?</span></p>
<p><span class="Bold">Do not take an NSAID medicine: </span></p>
<ul>
<li>if you had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin or any other NSAID medicine </li>
<li>for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> right before or after heart bypass surgery</li>
</ul>
<p><span class="Bold">Tell your healthcare provider: </span></p>
<ul>
<li>about all of your medical conditions.</li>
<li>about all of the medicines you take. NSAIDs and some other medicines can interact with each other and cause serious side effects. <span class="Bold">Keep a list of your medicines to show to your healthcare provider and pharmacist. </span>
</li>
<li>if you are pregnant. <span class="Bold">NSAID medicines should not be used by pregnant women late in their pregnancy.</span>
</li>
<li>if you are breastfeeding. <span class="Bold">Talk to your doctor.</span>
</li>
</ul>
<p><span class="Bold">What are the possible side effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)? </span></p>
<a name="id_22f1595d-023a-4d02-b98f-6103cb7d616d"></a><table width="0.000">
<col>
<col>
<tbody class="Headless"><tr class="First Last">
<td class="Botrule Rrule" align="left" valign="top">
<p class="First"><span class="Bold">Serious side effects include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span></li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span></li>
<li>high blood pressure</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)</li>
<li>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine</li>
<li>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span></li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span></li>
<li>liver problems including <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span></li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
</ul>
</td>
<td class="Botrule" align="left" valign="top">
<p class="First"><span class="Bold">Other side effects include:</span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>gas</li>
<li>heart burn</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul>
</td>
</tr></tbody>
</table>
<p><span class="Bold">Get emergency help right away if you have any of the following symptoms: </span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing </li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> </li>
<li>weakness  in one part or side of your body </li>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat </li>
</ul>
<p><span class="Bold">Stop your NSAID medicine and call your healthcare provider right away if you have any of the following symptoms: </span></p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </li>
<li>more tired or weaker than usual </li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> </li>
<li>your skin or eyes look yellow </li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> </li>
<li>flu-like symptoms </li>
<li>vomit blood </li>
<li>there is blood in your bowel movement or it is black and sticky like tar </li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> </li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the arms and legs, hands and feet </li>
</ul>
<p>These are not all the side effects with NSAID medicines. Talk to your healthcare provider or pharmacist for more information about NSAID medicines. </p>
<p><span class="Bold">Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</span></p>
<p><span class="Bold">Other information about Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) </span></p>
<ul>
<li>Aspirin is an NSAID medicine but it does not increase the chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span>. Aspirin can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the brain, stomach, and intestines. Aspirin can also cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestines. </li>
<li>Some of these NSAID medicines are sold in lower doses without a prescription (over-the-counter). Talk to your healthcare provider before using over-the-counter NSAIDs for more than 10 days.</li>
</ul>
<a name="id_e2c18ed5-ec4c-4030-ba2c-ec5bda14f959"></a><table width="0.000">
<caption><span>NSAID medicines that need a prescription</span></caption>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Generic Name</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Tradename</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Celecoxib</td>
<td class="Botrule Rrule" align="left" valign="top">Celebrex</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Diclofenac</td>
<td class="Botrule Rrule" align="left" valign="top">Cataflam, Voltaren, Arthrotec (combined with misoprostol)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Diflunisal</td>
<td class="Botrule Rrule" align="left" valign="top">Dolobid</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Etodolac</td>
<td class="Botrule Rrule" align="left" valign="top">Lodine, Lodine XL</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Fenoprofen</td>
<td class="Botrule Rrule" align="left" valign="top">Nalfon, Nalfon 200</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Flurbiprofen</td>
<td class="Botrule Rrule" align="left" valign="top">Ansaid</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Ibuprofen</td>
<td class="Botrule Rrule" align="left" valign="top">Motrin, Tab-Profen, Vicoprofen (combined with hydrocodone), Combunox (combined with oxycodone)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Indomethacin</td>
<td class="Botrule Rrule" align="left" valign="top">Indocin, Indocin SR, Indo-Lemmon, Indomethagan</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Ketoprofen</td>
<td class="Botrule Rrule" align="left" valign="top">Oruvail</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Ketorolac</td>
<td class="Botrule Rrule" align="left" valign="top">Toradol</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Mefenamic Acid</td>
<td class="Botrule Rrule" align="left" valign="top">Ponstel</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Meloxicam</td>
<td class="Botrule Rrule" align="left" valign="top">Mobic</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Nabumetone</td>
<td class="Botrule Rrule" align="left" valign="top">Relafen</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Naproxen</td>
<td class="Botrule Rrule" align="left" valign="top">Naprosyn, Anaprox, Anaprox DS, EC-Naproxyn, Naprelan, Naprapac (copackaged with lansoprazole)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Oxaprozin</td>
<td class="Botrule Rrule" align="left" valign="top">Daypro</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Piroxicam</td>
<td class="Botrule Rrule" align="left" valign="top">Feldene</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Sulindac</td>
<td class="Botrule Rrule" align="left" valign="top">Clinoril</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Tolmetin</td>
<td class="Botrule Rrule" align="left" valign="top">Tolectin, Tolectin DS, Tolectin 600</td>
</tr>
</tbody>
</table>
<p><span class="Italics">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Revised 06/2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_7bcb7b8c-dc76-4693-a4b5-153b45f11b1e"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 100 mg</span></p>
<p><span class="Bold"></span><br></p>
<p><span class="Bold">ATTENTION:</span><br><span class="Bold">Dispense with</span><br><span class="Bold">Medication Guide</span></p>
<p><span class="Bold"><br></span></p>
<p><span class="Bold">FLURBIPROFEN<br>TABLETS, USP<br>100 mg</span></p>
<p><span class="Bold">(Rx only)</span></p>
<p>Each tablet contains:<br>Flurbiprofen, USP <span class="Bold">. . . . </span>100 mg</p>
<p>Dispense in a tight, light-resistant<br>container as defined in the USP<br>using a child-resistant closure.</p>
<p>Keep container tightly closed.</p>
<p>Keep this and all medication<br>out of the reach of children.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F).<br>[See USP for Controlled Room<br>Temperature.]</span></p>
<p><span class="Bold">Protect from light.</span></p>
<p><span class="Bold">Usual Dosage:</span> See accompanying<br>prescribing information.</p>
<div class="Figure"><img alt="Flurbiprofen Tablets 100 mg Bottles" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c9449292-e81e-486a-84e1-bb9dd0f612c5&amp;name=3362.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FLURBIPROFEN 		
					</strong><br><span class="contentTableReg">flurbiprofen tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-3362(NDC:0378-0093)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FLURBIPROFEN</strong> (FLURBIPROFEN) </td>
<td class="formItem">FLURBIPROFEN</td>
<td class="formItem">100 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BROWN (beige) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">M;93</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-3362-0</td>
<td class="formItem">20  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-3362-1</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-3362-2</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074358</td>
<td class="formItem">02/24/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>805932c3-0a3a-4eac-a6ab-9b8cca1929bd</div>
<div>Set id: c9449292-e81e-486a-84e1-bb9dd0f612c5</div>
<div>Version: 1</div>
<div>Effective Time: 20120612</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
